Stock listing

Turquoise:GILDN Gilead Sciences, Inc. Share Price

UK listing (Turquoise) of Gilead Sciences, Inc. · home listing NASDAQ:GILD

Follow Gilead Sciences, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:GILD

$166.43 USD -2.55 (-1.5%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GILD

Past year +33.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$165.80 – $170.24 USDNov 20, 2026
Volume
7.56M sharesNov 20, 2026
Market cap
$206.4B USDAt the close on Nov 20, 2026 · price × 1.24B shares outstanding
52-week range
$116.88 – $176.58 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$929.4M USDMedian day 5.38M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Gilead Sciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GILD · Home$166.43 USD-2.55 (-1.5%)7,555,020$168.28$170.24$165.80$168.98Close on Nov 20, 2026
TSX:GILD$33.39 CAD-0.20 (-0.6%)5,300$33.59$33.87$33.39$33.59Close on Nov 20, 2026
Xetra:GIS€153.92 EUR+1.78 (+1.2%)534€153.12€154.96€150.92€152.14Close on Nov 20, 2026
Cboe Canada:GILD$33.82 CAD+0.62 (+1.9%)1,200$33.82$33.82$33.82$33.20Close on Nov 20, 2026
BMV:GILD$3,173.84 MXN+67.64 (+2.2%)221$3,173.84$3,173.84$3,173.84$3,106.20Close on Nov 19, 2026
Frankfurt:GIS€153.52 EUR+3.16 (+2.1%)790€152.16€154.04€152.16€150.36Close on Nov 20, 2026
B3:GILD3482.33 BRL-0.33 (-0.4%)14483.2583.2582.3382.66Close on Nov 19, 2026
Dusseldorf:GIS€153.22 EUR+0.94 (+0.6%)—€151.84€153.44€151.84€152.28Close on Nov 20, 2026
Munich:GIS€154.00 EUR-0.08 (-0.1%)—€154.00€154.00€154.00€154.08Close on Nov 20, 2026
Hamburg:GIS€153.92 EUR+2.70 (+1.8%)—€152.00€153.92€152.00€151.22Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GILD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$166.43-2.55-1.5%$168.28$170.24$165.807,555,020
$168.98-1.28-0.8%$169.15$170.63$167.364,818,627
$170.26+2.68+1.6%$166.12$171.36$165.726,220,601
$167.58-0.50-0.3%$171.47$171.80$166.754,582,767
$168.08+0.13+0.1%$168.55$169.12$166.943,637,151
$167.95-1.78-1.0%$171.18$171.70$167.934,228,274
$169.73-1.14-0.7%$169.45$170.47$168.374,874,882
$170.87+1.55+0.9%$170.44$171.15$167.614,830,415
$169.32+2.43+1.5%$169.00$170.11$165.994,289,261
$166.89-0.68-0.4%$164.11$169.03$164.005,695,172
$167.57-6.91-4.0%$174.54$176.58$167.0911,273,348
$174.48+7.01+4.2%$171.89$175.41$168.889,555,033
$167.47-2.86-1.7%$170.27$172.00$167.436,362,565
$170.33-0.35-0.2%$169.85$172.61$166.388,875,746
$170.68+5.07+3.1%$170.00$175.65$169.0011,363,966
$165.61+6.41+4.0%$162.99$165.70$160.868,345,119
$159.20+0.12+0.1%$157.30$160.83$156.044,846,215
$159.08+0.39+0.2%$156.42$159.28$155.764,931,456
$158.69+2.65+1.7%$157.62$159.69$157.526,037,050
$156.04-1.15-0.7%$156.47$157.65$155.766,070,932
$157.19+3.62+2.4%$154.24$157.42$153.006,210,518
$153.57-2.94-1.9%$154.73$155.42$151.716,220,836
$156.51+3.44+2.2%$155.37$157.48$154.025,793,495
$153.07-3.12-2.0%$155.39$157.24$152.926,835,294
$156.19-1.18-0.7%$157.32$157.58$155.627,770,900
$157.37+3.83+2.5%$156.39$160.51$156.028,287,500
$153.54+5.62+3.8%$148.19$153.76$147.485,756,500
$147.92-2.51-1.7%$151.16$151.16$147.265,558,100
$150.43-0.74-0.5%$151.84$152.26$149.805,791,400
$151.17+4.07+2.8%$147.23$151.44$146.105,802,000
$147.10+0.25+0.2%$146.73$147.59$144.654,489,500
$146.85+2.62+1.8%$145.28$148.60$144.855,096,700
$144.23-0.40-0.3%$145.11$146.14$142.603,723,400
$144.63-0.11-0.1%$143.21$145.16$142.796,137,600
$144.74-2.76-1.9%$147.65$148.00$144.005,043,900
$147.50-1.55-1.0%$149.44$149.44$147.194,438,500
$149.05-2.23-1.5%$150.88$151.28$148.985,357,200
$151.28-0.93-0.6%$150.18$152.63$148.795,322,400
$152.21+1.28+0.8%$149.80$152.74$149.415,076,500
$150.93+1.24+0.8%$150.05$151.00$148.025,284,300
$149.69-1.68-1.1%$151.10$152.98$149.595,074,700
$151.37-1.30-0.9%$153.60$154.20$150.066,191,700
$152.67+2.11+1.4%$150.65$153.28$148.655,080,000
$150.56+0.45+0.3%$150.11$152.10$148.225,569,200
$150.11-0.78-0.5%$150.56$153.23$149.5716,412,100
$150.89+3.21+2.2%$148.78$151.04$146.897,842,200
$147.68+1.38+0.9%$146.58$149.30$146.125,187,900
$146.30-0.11-0.1%$144.00$146.35$142.944,532,600
$146.41+2.69+1.9%$144.26$146.75$143.714,919,900
$143.72-1.09-0.8%$145.24$145.99$143.504,202,400
$144.81-0.84-0.6%$145.07$145.91$143.676,019,300
$145.65-0.99-0.7%$145.46$147.68$145.004,582,500
$146.64-4.36-2.9%$146.98$148.65$145.456,080,100
$151.00-0.22-0.1%$149.23$151.19$149.236,181,300
$151.22+1.61+1.1%$150.67$151.48$148.414,497,700
$149.61-0.31-0.2%$150.00$152.55$148.834,923,200
$149.92+3.58+2.4%$148.52$149.96$146.924,868,100
$146.34+0.66+0.5%$144.23$147.22$143.186,594,700
$145.68-3.18-2.1%$149.47$149.47$144.883,946,900
$148.86+0.77+0.5%$147.30$149.11$146.015,014,800
$148.09-0.68-0.5%$148.00$149.62$147.005,258,300
$148.77+2.03+1.4%$146.60$148.94$145.584,630,300
$146.74+0.62+0.4%$145.93$146.84$144.596,182,900
$146.12+2.68+1.9%$144.52$147.91$143.505,384,300
$143.44-4.16-2.8%$146.69$146.82$143.197,167,600

Splits

5 splits since 2001 · NASDAQ:GILD · every price before a split is adjusted for it

DayRatioWhat
2-for-1Split
2-for-1Split
2-for-1Split
2-for-1Split
2-for-1Split
Ticker
Turquoise:GILDN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Turquoise
Currency
USD

What changed lately

Latest news

Third Quarter 2026 Summary of Remarks

Oct 29, 2026

Closed $170.68 (+3.1%) on Oct 30, 2026

All Gilead Sciences, Inc. news

Gilead Sciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
85 in the last 12 months · 378 in all · newest Nov 16, 2026 · oldest 2020
Calls
31 calls with a replay · 31 with a transcript · latest Oct 29, 2026
Decks
57 decks · latest Oct 29, 2026

Where Gilead Sciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GILD · Home listingNASDAQUnited StatesUSD
gettex:GISgettexGermanyEUR
Tradegate:GISTradegateGermanyEUR
BCBA:GILDBCBAArgentinaARS
TSX:GILDTSXCanadaCAD
Xetra:GISXetraGermanyEUR
Cboe Canada:GILDCboe CanadaCanadaCAD
Milan:1GILDMilanItalyEUR
LS Exchange:885823LS ExchangeGermanyEUR
BMV:GILDBMVMexicoMXN
Lang & Schwarz:885823Lang & SchwarzGermanyEUR
Frankfurt:GISFrankfurtGermanyEUR
BCBA:GILDDBCBAArgentinaUSD
Stuttgart:GISStuttgartGermanyEUR
B3:GILD34B3BrazilBRL
BOATS:GILDBOATSUnited StatesUSD
SIX Swiss:GILDSIX SwissSwitzerlandCHF
LSIN:0QYQLSINUnited KingdomUSD
BIVA:GILDBIVAMexicoMXN
EUROTLX:4GILDEUROTLXItalyEUR
BCBA:GILDCBCBAArgentinaUSD
VIE:GILDViennaAustriaEUR
Dusseldorf:GISDusseldorfGermanyEUR
Munich:GISMunichGermanyEUR
Aquis:GISDAquisUnited KingdomEUR
BCS:GILDBCSChileUSD
Hamburg:GISHamburgGermanyEUR
BCS:GILDCLBCSChileCLP
Aquis:GISDAquisUnited KingdomEUR
BVL:GILDUSBVLPeruPEN
BX Swiss:GISBX SwissSwitzerlandCHF
BCBA:GILDBBCBAArgentinaARS
Frankfurt:GIS0FrankfurtGermanyEUR
Hanover:GISHanoverGermanyEUR
SIX Swiss:GILD.USDSIX SwissSwitzerlandUSD
Turquoise:GILDN · This pageTurquoiseUnited KingdomUSD
BCBA:GILD.CIBCBAArgentinaARS

Valuation

EV/sales 7.3× against a median of 7.1×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$226.2B USD
P/E
Loss
EV/sales
7.3×
EV/EBITDA
Negative EBITDA
Price/book
15.8×
Gross margin
79.9%
Operating margin
−7.6%
Net margin
−12.5%
Debt to equity
2.0×
Beta vs S&P 500
0.36

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Gilead Sciences, Inc. · NASDAQ:GILDUS$206.4BUS$226.2Bn/a7.3×n/a15.8×−12.5%2.0×0.36
Amgen Inc. · NASDAQ:AMGNUS$235.6BUS$276.5B25.1×7.1×15.8×16.4×24.1%3.8×0.48
Regeneron Pharmaceuticals, Inc. · NASDAQ:REGNUS$93.57BUS$86.26B19.4×5.1×n/a2.8×28.5%0.1×0.36
CSL Limited · ASX:CSLUS$62.67BUS$72.05Bn/a4.6×14.3×4.2×−16.4%0.7×n/a
Biogen Inc. · NASDAQ:BIIBUS$36.89BUS$42.88B106×4.2×n/a1.9×3.4%0.4×0.34
Genmab A/S · OMXCOP:GMABUS$31.30BUS$34.64B42.9×8.1×24.4×4.9×17.0%0.8×n/a
Insmed Incorporated · NASDAQ:INSMUS$31.01BUS$30.41Bn/a20.0×n/a42.7×−39.9%0.8×0.01
Roivant Sciences Ltd. · NASDAQ:ROIVUS$27.92BUS$23.82Bn/a580×n/a7.0×−838.2%0.0×1.00
Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNYUS$19.26BUS$15.68B7.3×n/an/a5.3×n/a0.0×0.58
Ascendis Pharma A/S · NASDAQ:ASNDUS$16.73BUS$16.15B17.1×12.2×61.1×10.0×73.5%0.3×0.49
Exelixis, Inc. · NASDAQ:EXELUS$15.77BUS$14.88B17.8×6.0×n/a8.6×35.4%0.0×0.69
Median of the othersUS$31.15BUS$32.52B19.4×7.1×20.1×6.2×17.0%0.3×0.49

Forecasts

15 strong buy · 6 buy · 5 hold · 1 sell · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
175.92 USD · Analysts' mean
EPS, year to Dec 2026
-0.99 · 26 analysts
Revenue, year to Dec 2026
31.38B · 25 analysts

Team and board

Officers

OfficerRole
Daniel O’DayChairman and Chief Executive Officer
Andrew DickinsonChief Financial Officer
Jeffrey A. BluestonePresident
Keeley Cain WettanExecutive Vice President & General Counsel, Legal and Compliance
Cindy PerettieExecutive Vice President, Kite
Flavius MartinExecutive Vice President, Research
Jyoti MehraExecutive Vice President, Human Resources
Dietmar BergerChief Medical Officer
Johanna MercierChief Commercial & Corporate Affairs Officer

Board

DirectorRole
Daniel O’DayChairman and Chief Executive Officer
Anthony WeltersLead Independent Director
Harish ManwaniSenior Operating Partner
Jacqueline K. BartonProfessor Emerita, California Institute of Technology
Sandra J. HorningDirector
Ted W. LoveDirector

Events

Calls

CallWhenStatus
Gilead Sciences (NASDAQ:GILD) Q3 2026 Earnings CallThu, Oct 29, 2026 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q2 2026 Earnings CallTue, Aug 04, 2026 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q1 2026 Earnings CallThu, May 07, 2026 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q4 2025 Earnings CallTue, Feb 10, 2026 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q3 2025 Earnings CallThu, Oct 30, 2025 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q2 2025 Earnings CallThu, Aug 07, 2025 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q1 2025 Earnings CallThu, Apr 24, 2025 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q4 2024 Earnings CallTue, Feb 11, 2025 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q3 2024 Earnings CallWed, Nov 06, 2024 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q2 2024 Earnings CallThu, Aug 08, 2024 · 4:30 PM ETReplay
All 31 calls
CallWhenStatus
Gilead Sciences (NASDAQ:GILD) Q1 2024 Earnings CallThu, Apr 25, 2024 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q4 2023 Earnings CallTue, Feb 06, 2024 · 5:00 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q3 2023 Earnings CallTue, Nov 07, 2023 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q2 2023 Earnings CallThu, Aug 03, 2023 · 5:00 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q1 2023 Earnings CallThu, Apr 27, 2023 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q4 2022 Earnings CallThu, Feb 02, 2023 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q3 2022 Earnings CallThu, Oct 27, 2022 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q2 2022 Earnings CallTue, Aug 02, 2022Replay
Gilead Sciences (NASDAQ:GILD) Q1 2022 Earnings CallThu, Apr 28, 2022 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q4 2021 Earnings CallTue, Feb 01, 2022 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q3 2021 Earnings CallThu, Oct 28, 2021 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q2 2021 Earnings CallThu, Jul 29, 2021 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q1 2021 Earnings CallThu, Apr 29, 2021 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q4 2020 Earnings CallThu, Feb 04, 2021 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q3 2020 Earnings CallThu, Oct 29, 2020Replay
Gilead Sciences (NASDAQ:GILD) Q2 2020 Earnings CallThu, Jul 30, 2020Replay
Gilead Sciences (NASDAQ:GILD) Q1 2020 Earnings CallThu, Apr 30, 2020 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q4 2019 Earnings CallTue, Feb 04, 2020 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q3 2019 Earnings CallThu, Oct 24, 2019 · 4:30 PM ETReplay
Gilead Sciences (NASDAQ:GILD) Q2 2019 Earnings CallTue, Jul 30, 2019Replay
Gilead Sciences (NASDAQ:GILD) Q1 2019 Earnings CallThu, May 02, 2019 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 29, 2026 · After close+3.1%
Q2 2026Aug 4, 2026 · After close−2.6%
Q1 2026May 7, 2026 · After close−2.0%
Q4 2025Feb 10, 2026 · After close+5.8%
Q3 2025Oct 30, 2025 · After close+1.1%
Q2 2025Aug 7, 2025 · After close+8.3%
Q1 2025Apr 24, 2025 · After close−2.8%
Q4 2024Feb 4, 2025 · After close+1.7%
Q3 2024Nov 6, 2024 · After close+6.8%
Q2 2024Aug 8, 2024 · After close−2.5%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 25, 2024 · After close+0.2%
Q4 2023Feb 6, 2024 · After close−4.3%
Q3 2023Nov 7, 2023 · After close−3.4%
Q2 2023Aug 3, 2023 · After close+4.2%
Q1 2023Apr 27, 2023 · After close−1.6%
Q4 2022Feb 2, 2023 · After close+3.8%
Q3 2022Oct 27, 2022 · After close+12.9%
Q2 2022Aug 2, 2022 · After close+4.6%
Q1 2022Apr 28, 2022 · After close−3.6%
Q4 2021Feb 1, 2022 · After close−3.9%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings36 slidesOct 29, 2026
Q2 2026 Earnings PresentationEarnings36 slidesAug 4, 2026
Q1 2026 Earnings PresentationEarnings35 slidesMay 7, 2026
Merger or Acquisition (April 2026)Merger or acquisition10 slidesApr 7, 2026
Q4 2025 Earnings PresentationEarnings40 slidesFeb 10, 2026
J.P. Morgan Healthcare Conference 2026Conference24 slidesJan 12, 2026
Q3 2025 Earnings PresentationEarnings35 slidesOct 30, 2025
Q2 2025 Earnings PresentationEarnings35 slidesAug 7, 2025
fellowship program 2025 guida per la presentazione29 slidesJun 23, 2025
community award program 2025 guida per la presentazione29 slidesJun 23, 2025
Show 50 decks
DeckKindSlidesDate
Q1 2025 Earnings PresentationEarnings33 slidesApr 24, 2025
Q4 2024 Earnings PresentationEarnings40 slidesFeb 11, 2025
J.P. Morgan Healthcare Conference 2025Conference22 slidesJan 13, 2025
Investor Day (December 2024)Investor day82 slidesDec 10, 2024
Q3 2024 Earnings PresentationEarnings39 slidesNov 6, 2024
Fact Sheet (September 2024)Fact sheet1 slideSep 12, 2024
Q2 2024 Earnings PresentationEarnings39 slidesAug 8, 2024
Q1 2024 Earnings PresentationEarnings38 slidesApr 25, 2024
Investor Day (March 2024)Investor day88 slidesMar 14, 2024
Q4 2023 Earnings PresentationEarnings40 slidesFeb 6, 2024
J.P. Morgan Healthcare Conference 2024Conference24 slidesJan 8, 2024
data publication other medical grants 2024 guida per la presentazione26 slides2024
Q3 2023 Earnings PresentationEarnings38 slidesNov 7, 2023
Technical Presentation (August 2023)Technical11 slidesAug 16, 2023
Q2 2023 Earnings PresentationEarnings39 slidesAug 3, 2023
Q1 2023 Earnings PresentationEarnings33 slidesApr 27, 2023
Q4 2022 Earnings PresentationEarnings38 slidesFeb 2, 2023
J.P. Morgan Healthcare Conference 2023Conference22 slidesJan 9, 2023
Arcus Biosciences — Technical Presentation (December 2022)Technical21 slidesDec 20, 2022
Q3 2022 Earnings PresentationEarnings38 slidesOct 27, 2022
Q2 2022 Earnings PresentationEarnings36 slidesAug 2, 2022
Q1 2022 Earnings PresentationEarnings35 slidesApr 28, 2022
Q4 2021 Earnings PresentationEarnings36 slidesFeb 1, 2022
40th Annual J.P. Morgan Healthcare Conference 2022Conference19 slidesJan 10, 2022
Q3 2021 Earnings PresentationEarnings34 slidesOct 28, 2021
Q2 2021 Earnings PresentationEarnings31 slidesJul 29, 2021
Q1 2021 Earnings PresentationEarnings32 slidesApr 29, 2021
Q4 2020 Earnings PresentationEarnings51 slidesFeb 4, 2021
39th Annual J.P. Morgan Healthcare Conference (January 2021)Conference30 slidesJan 11, 2021
Q3 2020 Earnings PresentationEarnings53 slidesOct 29, 2020
Merger or Acquisition (September 2020)Merger or acquisition16 slidesSep 13, 2020
Q2 2020 Earnings PresentationEarnings44 slidesJul 30, 2020
Q1 2020 Earnings PresentationEarnings67 slidesApr 30, 2020
Q4 2019 Earnings PresentationEarnings59 slidesFeb 4, 2020
38th Annual J.P. Morgan Healthcare Conference (January 2020)Conference28 slidesJan 13, 2020
Q3 2019 Earnings PresentationEarnings47 slidesOct 24, 2019
Q2 2019 Earnings PresentationEarnings50 slidesJul 30, 2019
Merger or Acquisition (July 2019)Merger or acquisition12 slidesJul 14, 2019
Merger or Acquisition (August 2017)Merger or acquisition24 slidesAug 28, 2017
35th Annual J.P. Morgan Healthcare Conference (January 2017)Conference33 slidesJan 9, 2017

This page holds 50 of 57 decks. Open Decks

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue29.4B28.8B27.1B27.3B27.3B24.7B22.4B22.1B26.1B30.4B
Cost of revenue6.23B6.25B6.50B5.66B6.60B4.57B4.67B4.85B4.37B4.26B
Gross profit23.2B22.5B20.6B21.6B20.7B20.1B17.8B17.3B21.7B26.1B
Research and development5.80B5.91B5.72B4.98B4.60B4.93B9.11B5.02B3.73B5.10B
Selling, general and administrative5.77B6.09B6.09B5.67B5.25B5.15B4.38B4.06B3.88B3.40B
Operating income10.0B1.66B7.61B7.33B9.92B4.07B4.29B8.20B14.1B17.6B
Depreciation and amortization370.0M381.0M354.0M323.0M329.0M288.0M255.0M226.0M233.0M177.0M
EBITDA10.4B2.04B7.96B7.65B10.2B4.36B4.54B8.43B14.4B17.8B
Interest expense1.02B977.0M944.0M935.0M1.00B984.0M995.0M1.08B1.12B964.0M
Income before tax9.80B690.0M6.86B5.81B8.28B1.67B5.16B7.80B13.5B17.1B
Income tax1.29B211.0M1.25B1.25B2.08B1.58B-204.0M2.34B8.88B3.61B
Net income8.51B480.0M5.67B4.59B6.22B123.0M5.39B5.46B4.63B13.5B
Earnings per share, basic6.840.384.543.664.960.104.244.203.5410.08
Earnings per share, diluted6.780.384.503.644.930.104.224.173.519.94

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents7.56B9.99B6.08B5.41B5.34B6.00B11.6B17.9B7.59B8.23B
Short-term investments68.0M01.18B973.0M1.18B1.41B12.7B12.1B17.9B3.67B
Receivables4.91B4.42B4.66B4.78B4.49B4.89B3.58B3.33B3.85B4.51B
Inventory1.77B1.71B1.79B1.51B1.62B1.68B922.0M814.0M801.0M1.59B
Current assets18.3B19.2B16.1B14.4B14.8B16.0B30.3B35.8B31.8B19.6B
Property, plant and equipment5.61B5.41B5.32B5.47B5.12B4.97B4.50B4.01B3.29B2.87B
Goodwill8.31B8.31B8.31B8.31B8.33B8.11B4.12B4.12B4.16B1.17B
Total assets59.0B59.0B62.1B63.2B68.0B68.4B61.6B63.7B70.3B57.0B
Accounts payable715.0M833.0M550.0M905.0M705.0M844.0M713.0M790.0M814.0M1.21B
Current liabilities11.8B12.0B11.3B11.2B11.6B11.4B9.76B10.6B11.6B9.22B
Long-term debt22.1B24.9B23.2B23.0B25.2B28.6B22.1B24.6B30.8B26.3B
Total debt24.9B26.7B25.0B25.2B26.7B31.4B24.6B27.3B33.5B26.3B
Shareholders' equity22.7B19.3B22.8B21.2B21.1B18.2B22.5B21.4B20.4B18.9B
Shares outstanding1.24B1.25B1.25B1.25B1.25B1.25B1.27B1.28B1.31B1.31B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations10.0B10.8B8.01B9.07B11.4B8.17B9.14B8.40B11.9B17.0B
Capital spending-563.0M-523.0M-585.0M-728.0M-579.0M-650.0M-825.0M-924.0M-590.0M-748.0M
Free cash flow9.46B10.3B7.42B8.34B10.8B7.52B8.32B7.48B11.3B16.3B
Cash from investing-4.79B-3.45B-2.27B-2.47B-3.13B-14.6B-7.82B14.4B-16.1B-12.0B
Cash from financing-7.75B-3.43B-5.13B-6.47B-8.88B770.0M-7.63B-12.3B3.39B-9.72B
Dividends paid-4.00B-3.92B-3.81B-3.71B-3.60B-3.45B-3.22B-2.97B-2.73B-2.46B
Share buybacks-1.92B-1.15B-1.00B-1.40B-546.0M-1.58B-1.75B-2.90B-954.0M-11.0B
Change in cash-2.43B3.91B673.0M74.0M-659.0M-5.63B-6.31B10.4B-641.0M-4.62B

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 6, 2026Big-stake noticeSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
144 · Notice of proposed saleNov 6, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
13F-HR · Fund holdings reportNov 5, 2026Fund holdings reportSEC
144 · Notice of proposed saleNov 4, 2026Other filingsSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
144 · Notice of proposed saleOct 30, 2026Other filingsSEC
10-Q · Quarterly reportOct 29, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026ResultsSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipSep 23, 2026Insider tradeSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
144 · Notice of proposed saleAug 26, 2026Other filingsSEC
N-PXAug 26, 2026Other filingsSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
144 · Notice of proposed saleAug 20, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 7, 2026Big-stake noticeSEC
S-3ASR · Registration statementAug 6, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
8-K · Current reportAug 4, 2026ResultsSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
13F-HR · Fund holdings reportAug 3, 2026Fund holdings reportSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 27, 2026Big-stake noticeSEC
8-K · Current reportMay 20, 2026Material contractSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
424B5 · ProspectusMay 18, 2026Offer documentSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
FWP · Free writing prospectusMay 14, 2026Offer documentSEC
424B5 · ProspectusMay 14, 2026Offer documentSEC
13F-HR · Fund holdings reportMay 8, 2026Fund holdings reportSEC
S-8 · Registration statement for employee plansMay 7, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
8-K · Current reportMay 4, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
144 · Notice of proposed saleApr 28, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 28, 2026Big-stake noticeSEC
8-K · Current reportApr 28, 2026Current reportSEC
SC TO-T/AApr 28, 2026Acquisition or disposalSEC
SC TO-T/AApr 17, 2026Acquisition or disposalSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
SC TO-T/AApr 1, 2026Acquisition or disposalSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
144 · Notice of proposed saleMar 27, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersMar 20, 2026Annual reportSEC
DEFA14A · Additional proxy materialMar 20, 2026Meeting noticeSEC
DEF 14A · Proxy statementMar 20, 2026Meeting noticeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
SC TO-TMar 6, 2026Acquisition or disposalSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
10-K · Annual reportFeb 24, 2026Annual reportSEC
SC TO-CFeb 23, 2026Other filingsSEC
SCHEDULE 13D · Big-stake noticeFeb 23, 2026Big-stake noticeSEC
SC TO-CFeb 23, 2026Other filingsSEC
8-K · Current reportFeb 23, 2026Material contractSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
3 · Initial statement of ownershipFeb 12, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
13F-HR · Fund holdings reportFeb 12, 2026Fund holdings reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
8-K · Current reportFeb 10, 2026ResultsSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 5, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
144 · Notice of proposed saleJan 28, 2026Other filingsSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
144 · Notice of proposed saleJan 23, 2026Other filingsSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
144 · Notice of proposed saleNov 28, 2025Other filingsSEC
144 · Notice of proposed saleNov 28, 2025Other filingsSEC
144 · Notice of proposed saleNov 26, 2025Other filingsSEC
8-K · Current reportNov 19, 2025Management or board changeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
13F-HR · Fund holdings reportNov 13, 2025Fund holdings reportSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
8-K · Current reportOct 30, 2025ResultsSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
144 · Notice of proposed saleOct 28, 2025Other filingsSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
8-K · Current reportOct 6, 2025Current reportSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipSep 30, 2025Insider tradeSEC
144 · Notice of proposed saleSep 29, 2025Other filingsSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
144 · Notice of proposed saleSep 15, 2025Other filingsSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Gilead Sciences, Inc.’s releases · as of Oct 23, 2026

Common shares
1,240,338,614
Fully diluted
1,240,338,614

Fully diluted

LineSharesAs of
Common shares1,240,338,614Oct 23, 2026

Share count over time

CountShares
Oct 23, 20261,240,338,614

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard131M10.5%US$19.5BSep 30, 2026
BlackRock125M10.1%US$18.7BSep 30, 2026
Capital Group61.5M5.0%US$9.16BSep 30, 2026
State Street61M4.9%US$9.09BSep 30, 2026
Fidelity58.3M4.7%US$8.68BSep 30, 2026
Invesco38.7M3.1%US$5.76BSep 30, 2026
Geode Capital30.2M2.4%US$4.49BSep 30, 2026
T. Rowe Price27.7M2.2%US$4.13BSep 30, 2026
Morgan Stanley23.8M1.9%US$3.54BSep 30, 2026
JPMorgan23.1M1.9%US$3.49BSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Dodge & Cox21.8M1.8%US$3.25BSep 30, 2026
Bank of America19.2M1.6%US$2.87BSep 30, 2026
UBS15.9M1.3%US$2.37BSep 30, 2026
BNY14.8M1.2%US$2.2BSep 30, 2026
Goldman Sachs14.6M1.2%US$2.18BSep 30, 2026
Northern Trust13.7M1.1%US$2.05BSep 30, 2026
Wellington12.2M0.99%US$1.82BSep 30, 2026
Sun Life11.5M0.93%US$1.77BSep 30, 2026
Amundi11.3M0.91%US$1.68BSep 30, 2026
Legal & General10.4M0.84%US$1.55BSep 30, 2026
DWS9.61M0.78%US$1.43BSep 30, 2026
Schwab8.28M0.67%US$1.23BSep 30, 2026
Dimensional7.8M0.63%US$1.16BSep 30, 2026
Ameriprise7.57M0.61%US$1.13BSep 30, 2026
BNP Paribas7.24M0.58%US$1.08BSep 30, 2026
Nuveen7.13M0.58%US$1.06BSep 30, 2026
Boston Partners6.52M0.53%US$970MSep 30, 2026
Wells Fargo6.34M0.51%US$945MSep 30, 2026
Janus Henderson5.58M0.45%US$831MSep 30, 2026
RBC5.47M0.44%US$815MSep 30, 2026
Nordea Investment Management AB5.33M0.43%US$802MSep 30, 2026
AllianceBernstein5.06M0.41%US$755MSep 30, 2026
Nomura4.86M0.39%US$725MSep 30, 2026
MUFG4.74M0.38%US$706MSep 30, 2026
BMO3.84M0.31%US$572MSep 30, 2026
Franklin Templeton3.66M0.30%US$637MSep 30, 2026
Robeco Institutional Asset Management B.V.3.44M0.28%US$513MSep 30, 2026
HSBC3.41M0.27%US$509MSep 30, 2026
Swiss National Bank3.4M0.27%US$506MSep 30, 2026
California Public Employees Retirement System3.2M0.26%US$477MSep 30, 2026
Barclays3.14M0.25%US$468MSep 30, 2026
Man Group plc3.11M0.25%US$463MSep 30, 2026
National Pension Service3.08M0.25%US$459MSep 30, 2026
First Trust3.07M0.25%US$457MSep 30, 2026
American Century3.01M0.24%US$448MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.2.97M0.24%US$443MSep 30, 2026
Swedbank AB2.88M0.23%US$429MSep 30, 2026
Allianz2.73M0.22%US$406MSep 30, 2026
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main2.66M0.21%US$397MSep 30, 2026
Citigroup Inc2.5M0.20%US$373MSep 30, 2026

This page holds 50 of 2,321 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund39.4M3.2%US$4.98BJun 30, 2026
Vanguard 500 Index Fund32.2M2.6%US$4.06BJun 30, 2026
Invesco QQQ Trust, Series 126.4M2.1%US$3.33BJun 30, 2026
Dodge & Cox Stock Fund17.3M1.4%US$2.18BJun 30, 2026
iShares Core S&P 500 ETF17.1M1.4%US$2.16BJun 30, 2026
Fidelity 500 Index Fund15.9M1.3%US$2.13BMay 31, 2026
Income Fund of America15.5M1.2%US$2.02BJul 31, 2026
Vanguard Value Index Fund11.8M0.95%US$1.49BJun 30, 2026
Fidelity Contrafund11.4M0.92%US$1.44BJun 30, 2026
Washington Mutual Investors Fund10.3M0.83%US$1.34BJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
American Balanced Fund9.64M0.78%US$1.22BJun 30, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF8.77M0.71%US$1.11BJun 30, 2026
Capital Income Builder8.05M0.65%US$1.05BJul 31, 2026
Vanguard Dividend Appreciation Index Fund7.02M0.57%US$915MJul 31, 2026
Vanguard Institutional Index Fund6.74M0.54%US$852MJun 30, 2026
JPMorgan Large Cap Growth Fund6.57M0.53%US$830MJun 30, 2026
Vanguard Equity Income Fund6.13M0.49%US$775MJun 30, 2026
American Mutual Fund5.42M0.44%US$706MJul 31, 2026
Invesco NASDAQ 100 ETF5.27M0.43%US$709MMay 31, 2026
Vanguard High Dividend Yield Index Fund5M0.40%US$651MJul 31, 2026
iShares Biotechnology ETF4.92M0.40%US$622MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund4.71M0.38%US$633MMay 31, 2026
T. Rowe Price Value Fund, Inc.4.09M0.33%US$517MJun 30, 2026
Fidelity Blue Chip Growth Fund3.95M0.32%US$514MJul 31, 2026
Capital World Growth & Income Fund3.95M0.32%US$531MMay 31, 2026
Vanguard Health Care Index Fund3.73M0.30%US$501MMay 31, 2026
Columbia Dividend Income Fund3.66M0.30%US$492MMay 31, 2026
State Street(R) SPDR(R) Portfolio S&P 500(R) ETF2.96M0.24%US$374MJun 30, 2026
iShares Core Dividend Growth ETF2.92M0.24%US$381MJul 31, 2026
iShares Russell 1000 Value ETF2.77M0.22%US$351MJun 30, 2026
Schwab S&P 500 Index Fund2.77M0.22%US$361MJul 31, 2026
Pacer US Cash Cows 100 ETF2.77M0.22%US$360MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.2.67M0.22%US$337MJun 30, 2026
MFS Growth Fund2.58M0.21%US$347MMay 31, 2026
Fidelity Contrafund K62.45M0.20%US$310MJun 30, 2026
Fidelity Total Market Index Fund2.35M0.19%US$315MMay 31, 2026
iShares MSCI USA Quality Factor ETF2.19M0.18%US$286MJul 31, 2026
Disciplined Value Fund2.15M0.17%US$272MJun 30, 2026
Fidelity Series Value Discovery Fund2.09M0.17%US$272MJul 31, 2026
Fidelity OTC Portfolio2.07M0.17%US$270MJul 31, 2026
T. Rowe Price Dividend Growth Fund, Inc.1.9M0.15%US$240MJun 30, 2026
Fidelity Series Total Market Index Fund1.9M0.15%US$255MMay 31, 2026
Select Biotechnology Portfolio1.89M0.15%US$254MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio1.84M0.15%US$248MMay 29, 2026
Vanguard Wellesley Income Fund1.75M0.14%US$221MJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account1.68M0.14%US$212MJun 30, 2026
T. Rowe Price U.S. Large-Cap Core Fund, Inc.1.67M0.13%US$211MJun 30, 2026
Fidelity Equity-Income Fund1.67M0.13%US$217MJul 31, 2026
WisdomTree U.S. Quality Dividend Growth Fund1.65M0.13%US$208MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF1.6M0.13%US$202MJun 30, 2026

This page holds 50 of 1,338 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Dickinson Andrew D
Officer: Chief Financial Officer
Sale3,000USD 171.47US$514KNov 16, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale13,922USD 169.97US$2.37MNov 16, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale13,178USD 171.09US$2.25MNov 16, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale900USD 171.69US$155KNov 16, 2026
Kramer Kelly A.
Director
Sale1,676USD 168.23US$282KNov 12, 2026
Kramer Kelly A.
Director
Sale3,800USD 169.44US$644KNov 12, 2026
Kramer Kelly A.
Director
Sale4,700USD 170.49US$801KNov 12, 2026
Kramer Kelly A.
Director
Sale200USD 171.44US$34,288Nov 12, 2026
Cain Wettan Keeley M
Officer: EVP Gen Counsel, Legal & Comp
Sale3,399USD 164.11US$558KNov 6, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale9,810USD 175.17US$1.72MNov 5, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale102,619USD 175.16US$18MNov 4, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale1,600USD 167.40US$268KNov 2, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale1,700USD 168.10US$286KNov 2, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale1,904USD 169.27US$322KNov 2, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale7,796USD 170.35US$1.33MNov 2, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale2,000USD 171.06US$342KNov 2, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale15,881USD 175.25US$2.78MOct 30, 2026
Dickinson Andrew D
Officer: Chief Financial Officer
Sale3,000USD 156.22US$469KOct 15, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale3,000USD 156.22US$469KOct 15, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale12,000USD 147.72US$1.77MOct 1, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale3,000USD 148.63US$446KOct 1, 2026
Dickinson Andrew D
Officer: Chief Financial Officer
Sale3,000USD 145.29US$436KSep 15, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale1,600USD 143.69US$230KSep 15, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale800USD 144.46US$116KSep 15, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale600USD 145.29US$87,174Sep 15, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale1,600USD 147.51US$236KSep 1, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale7,992USD 148.36US$1.19MSep 1, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale5,408USD 149.38US$808KSep 1, 2026
Welters Anthony
Director
Sale3,118USD 148.31US$462KAug 26, 2026
Welters Anthony
Director
Sale4,600USD 148.82US$685KAug 26, 2026
Welters Anthony
Director
Sale3,402USD 148.24US$504KAug 26, 2026
Welters Anthony
Director
Sale6,880USD 148.82US$1.02MAug 26, 2026
Bluestone Jeffrey
Director
Sale1,165USD 143.75US$167KAug 20, 2026
Bluestone Jeffrey
Director
Sale1,816USD 144.92US$263KAug 20, 2026
Bluestone Jeffrey
Director
Sale1,658USD 145.73US$242KAug 20, 2026
Bluestone Jeffrey
Director
Sale26USD 146.36US$3,805Aug 20, 2026
Bluestone Jeffrey
Director
Sale335USD 146.26US$48,997Aug 20, 2026
Dickinson Andrew D
Officer: Chief Financial Officer
Sale3,000USD 138.36US$415KAug 17, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale16,530USD 137.37US$2.27MAug 17, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale11,470USD 138.04US$1.58MAug 17, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale6,700USD 129.66US$869KAug 3, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale7,700USD 130.80US$1.01MAug 3, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale600USD 131.34US$78,804Aug 3, 2026
Dickinson Andrew D
Officer: Chief Financial Officer
Sale3,000USD 129.93US$390KJul 15, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale3,000USD 129.92US$390KJul 15, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale11,900USD 126.09US$1.5MJul 1, 2026
O'Day Daniel Patrick
Director, Officer: Chairman & CEO
Sale3,100USD 127.08US$394KJul 1, 2026
Dickinson Andrew D
Officer: Chief Financial Officer
Sale3,000USD 125.40US$376KJun 15, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale1,480USD 123.42US$183KJun 15, 2026
Mercier Johanna
Officer: Chief Comm & Corp Aff Officer
Sale1,070USD 124.00US$133KJun 15, 2026

This page holds 50 of 63 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.8.20%102MMar 31, 2025Schedule 13G
Vanguard Capital Management LLC7.51%93.3MMar 31, 2026Schedule 13G
FMR LLC5.30%65.5MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ted W Love
Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past)
Director · Since at least Feb 1, 2024
Caroline Dorsa
Other companies: Duke Energy Corporation (Holding Company) (Director · Since at least May 6, 2021); Illumina, Inc. (Director · Since at least Jan 26, 2017); Biogen Inc. (Director · Since at least Jan 3, 2010); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Jun 14, 2022 · Past); Avaya Inc (SVP & Chief Financial Officer · Feb 7, 2007 – Oct 25, 2007 · Past); Public Service Enterprise Group Incorporated (Executive VP & CFO · Dec 1, 2006 – Aug 5, 2015 · Past)
SVP, Chief Financial Officer · Nov 5, 2007 – Jan 21, 2008 · Past
Sandra J. Horning
Other companies: Revolution Medicines, Inc. (Director · Since at least Nov 9, 2023); Olema Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2020); Moderna, Inc. (Director · Since at least Apr 29, 2020); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Foundation Medicine Inc (Director · Apr 7, 2015 – Apr 7, 2015 · Past)
Director · Since at least Jan 28, 2020
Harish Manwani
Other companies: QUALCOMM Incorporated (Director · Mar 10, 2020 – Apr 5, 2021 · Past); Nielsen Holdings PLC (Director · May 1, 2019 – Mar 18, 2021 · Past); Whirlpool Corporation (Director · Apr 16, 2019 – Apr 15, 2025 · Past)
Senior Operating Partner · Since at least May 7, 2019
John F. Milligan
Other companies: Kailera Therapeutics, Inc. (Board Chair · Since at least Apr 16, 2026); 4D Molecular Therapeutics, Inc. (Executive Chairman · Since at least Dec 10, 2020); Pacific Biosciences of California, Inc. (Chairman of the Board · Since at least Jul 17, 2013)
President and CEO, Director · Nov 7, 2013 – Nov 27, 2018 · Past
Kelly Kramer
Other companies: Figma Inc (Member of our Board of Directors · Since at least Jul 30, 2025); Snowflake Inc. (Director · Since at least Jul 2, 2025); Coinbase Global, Inc. (Director · Since at least Jun 14, 2025)
Director · Since at least May 7, 2025
Paul Carter
Other companies: Immatics N.V. (Non-Executive Director · Since at least Mar 18, 2026); Mallinckrodt Inc (Director · May 16, 2018 – Jun 16, 2022 · Past); Alder BioPharmaceuticals Inc (Director · Sep 28, 2015 – Oct 22, 2019 · Past)
EVP Commercial Ops · Jul 1, 2015 – Aug 1, 2016 · Past
Anthony Welters
Other companies: The Carlyle Group Inc. (Director · Since at least May 1, 2019); Loews Corporation (Director · May 14, 2019 – Mar 3, 2025 · Past)
Director · Since at least Oct 17, 2020
Johanna Mercier
Other companies: Neurocrine Biosciences, Inc. (Director · Since at least Apr 15, 2021); Arcus Biosciences, Inc. (Director · Jan 29, 2024 – Jan 29, 2024 · Past)
Chief Commercial & Corporate Affairs Officer · Since at least Jul 1, 2019
John McHutchison
Other companies: Assembly Biosciences, Inc. (Director · Since at least Aug 6, 2019); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past)
Chief Scientific Off/HeadR&D · Apr 23, 2018 – Feb 6, 2019 · Past
All 32 people
PersonSeat
Kevin E Lofton
Other companies: MiniMed Group, Inc. (Director · Since at least Mar 6, 2026); Medtronic plc. (Director · Since at least Apr 29, 2024)
Director · Dec 28, 2023 – Mar 28, 2024 · Past
Olsen Per Wold
Other companies: Amarin Corporation plc (Director · Jan 10, 2022 – Jan 10, 2023 · Past); PharmaNet Development Group Inc (Director · Jun 6, 2007 – Mar 20, 2009 · Past)
Director · Jan 28, 2010 – May 6, 2021 · Past
Taiyin Yang
Other companies: Kronos Bio Inc (Director · Since at least Mar 25, 2021); Kodiak Sciences Inc (Director · Since at least Dec 17, 2019)
SVP, Pharm Dev & Mfg · Jan 25, 2006 – May 8, 2007 · Past
Ted W. Love
Other companies: Jazz Pharmaceuticals plc (Director, Jazz Pharmaceuticals plc · Since at least Nov 5, 2025); Royalty Pharma plc (Board Member · Since at least Sep 29, 2025)
Director · Since at least May 4, 2026
Brett A Pletcher
Other companies: Cytokinetics, Incorporated (EVP, Chief Legal Officer · Aug 13, 2024 – Aug 30, 2024 · Past)
EVP,Corp Affairs & Gen Counsel · May 9, 2018 – Jun 10, 2022 · Past
Dietmar Berger
Other companies: Arcus Biosciences, Inc. (Director · Feb 6, 2025 – Feb 6, 2025 · Past)
Chief Medical Officer · Since at least Jan 2, 2025
Javier J. Rodriguez
Other companies: DaVita Inc. (Chief Executive Officer, Director · Since at least Apr 11, 2016)
Director · Since at least Jun 15, 2020
John W Madigan
Other companies: Boise Cascade, L.L.C. (Director · Feb 5, 2013 – Jun 2, 2014 · Past)
Director · May 6, 2009 – May 9, 2017 · Past
Kevin Young
Other companies: Quince Therapeutics, Inc. (Director · May 8, 2019 – Jun 8, 2020 · Past)
Chief Operating Officer · May 24, 2016 – Feb 15, 2018 · Past
Richard J. Whitley
Other companies: Dogwood Therapeutics, Inc. (Director · Since at least Dec 16, 2020)
Director · Mar 28, 2019 – May 6, 2021 · Past
Andrew DickinsonChief Financial Officer · Since at least Mar 31, 2026
Cindy PerettieExecutive Vice President, Kite · Since at least Apr 28, 2026
Daniel O’DayChairman and Chief Executive Officer · Since at least Feb 26, 2019
Erin BurkhartSVP, Controllership · Since at least Sep 22, 2026
Etienne DavignonDirector · Jan 26, 2006 – May 6, 2016 · Past
Flavius MartinExecutive Vice President, Research · Since at least Sep 8, 2026
Gayle E WilsonDirector · May 6, 2009 – May 5, 2020 · Past
Jacqueline K. BartonDirector · Since at least May 6, 2021
Jeffrey A. BluestoneDirector · Since at least May 7, 2025
Jyoti MehraExecutive Vice President, Human Resources · Since at least Nov 5, 2026
Keeley Cain WettanExecutive Vice President & General Counsel, Legal and Compliance · Since at least Mar 2, 2026
Sandra PattersonSVP, Controllership · Mar 1, 2023 – Mar 10, 2025 · Past

Open People

Log in to ask 6ix AI your own questions about Gilead Sciences, Inc.